{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.18","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.78","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.28","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"title":"Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.15","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"title":"Cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.68","value":"5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"Cycle 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.24","value":"5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Cycle 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.15","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Cycle 30"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' Positive change from baseline indicates improved health.","dispersionType":"Standard Deviation","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"MEAN","populationDescription":"Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Baseline to Cycle 30 (28 days per cycle)","title":"Change From Baseline in EuroQol 5-dimension 5-level (EQ-5D-5L) Visual Analogue Score (VAS)","type":"SECONDARY","unitOfMeasure":"Score on a scale"}